Moonlake Immunotherapeutics (MLTX) SEC Filings — 2025
10 SEC filings for Moonlake Immunotherapeutics (MLTX) in 2025.
Filings
- MoonLake Immunotherapeutics Files 8-K for Material Agreement — 8-K · Nov 5, 2025
- MoonLake's Losses Widen on Soaring R&D for Key Drug Sonelokimab — 10-Q · Nov 5, 2025
- MoonLake Immunotherapeutics Files 8-K — 8-K · Sep 29, 2025
- MoonLake Immunotherapeutics: No Revenue, Focus on Clinical Pipeline — 10-Q · Aug 5, 2025
- MoonLake Immunotherapeutics Files 8-K on Shareholder Vote Matters — 8-K · Jun 6, 2025
- MoonLake Immunotherapeutics Files Q1 2025 10-Q — 10-Q · May 12, 2025
- MoonLake to Acquire Elevate Bio — 8-K · Apr 29, 2025
- MoonLake Immunotherapeutics Files Definitive Proxy Statement — DEF 14A · Apr 22, 2025
- MoonLake Immunotherapeutics Files 8-K: Material Agreement — 8-K · Apr 3, 2025
- MoonLake Immunotherapeutics Files 2024 10-K — 10-K · Feb 26, 2025